Literature DB >> 3094944

Natural killer and antibody-dependent cellular cytotoxicity in cervical carcinoma patients.

M N Satam, J N Suraiya, J J Nadkarni.   

Abstract

Natural killer (NK) cell activity and antibody dependent cell-mediated cytotoxicity (ADCC) was measured in 62 untreated cervical carcinoma patients and 25 normal healthy women, using a short-term chromium release assay. A significant reduction in NK and ADCC activity was observed in disseminated disease than in localized disease, when compared with normal donors. The majority of the patients received radiotherapy and both NK and ADCC activity recovered after therapy. Furthermore, interferon-alpha was demonstrated to augment NK activity of peripheral blood mononuclear cells from healthy donors as well as patients. Also large granular lymphocytes separated on Percoll density gradient were the same in number in both the populations studied, although in cervical cancer there seemed to be a defect in killing activity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3094944     DOI: 10.1007/bf00205556

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  20 in total

1.  Separation of leukocytes from blood and bone marrow. Introduction.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

2.  Contactual lysis of antibody-coated chicken erythrocytes by purified lymphocytes.

Authors:  P Perlmann; H Perlmann
Journal:  Cell Immunol       Date:  1970-09       Impact factor: 4.868

3.  Role of non-conventional natural killer cells in resistance against syngeneic tumour cells in vivo.

Authors:  O Haller; M Hansson; R Kiessling; H Wigzell
Journal:  Nature       Date:  1977-12-15       Impact factor: 49.962

4.  Lysis of fresh human tumor cells by autologous large granular lymphocytes and T-lymphocytes: two distinct killing activities induced by coculture with autologous tumor.

Authors:  A Uchida; M Moore
Journal:  J Natl Cancer Inst       Date:  1984-12       Impact factor: 13.506

5.  Prospective study of natural cytotoxicity in peripheral blood of patients with nonlymphoid solid malignancies.

Authors:  L D Stewart; E W Ades
Journal:  Clin Immunol Immunopathol       Date:  1984-04

6.  Natural killer cell activity in patients with abnormalities of the uterine cervix.

Authors:  W Neill; M Norval
Journal:  Gynecol Obstet Invest       Date:  1984       Impact factor: 2.031

7.  Natural cytotoxicity and interferon production in human cancer: deficient natural killer activity and normal interferon production in patients with advanced disease.

Authors:  A S Kadish; A T Doyle; E H Steinhauer; N A Ghossein
Journal:  J Immunol       Date:  1981-11       Impact factor: 5.422

8.  Natural cytotoxicity in malignant and premalignant cervical neoplasia and enhancement of cytotoxicity with interferon.

Authors:  V Seltzer; A Doyle; A S Kadish
Journal:  Gynecol Oncol       Date:  1983-06       Impact factor: 5.482

9.  Human lymphocyte, monocyte, and neutrophil antibody-dependent cell-mediated cytotoxicity toward human erythrocytes.

Authors:  G M Shaw; P C Levy; A F LoBuglio
Journal:  Cell Immunol       Date:  1978-11       Impact factor: 4.868

10.  Augmentation of mouse natural killer activity and induction of interferon by tumor cells in vivo.

Authors:  J Y Djeu; K Y Huang; R B Herberman
Journal:  J Exp Med       Date:  1980-04-01       Impact factor: 14.307

View more
  2 in total

1.  Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach.

Authors:  Susan K Lutgendorf; Elizabeth Mullen-Houser; Daniel Russell; Koen Degeest; Geraldine Jacobson; Laura Hart; David Bender; Barrie Anderson; Thomas E Buekers; Michael J Goodheart; Michael H Antoni; Anil K Sood; David M Lubaroff
Journal:  Brain Behav Immun       Date:  2010-06-30       Impact factor: 7.217

2.  In vitro modulation of natural killer cell activity in non-Hodgkin's lymphoma patients after therapy.

Authors:  B A Mehta; M N Satam; S H Advani; J J Nadkarni
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.